Literature DB >> 6859994

Local and in-transit metastases following definitive excision for primary cutaneous malignant melanoma.

D F Roses, M N Harris, D Rigel, Z Carrey, R Friedman, A W Kopf.   

Abstract

A total of 672 consecutive patients with clinical stage I and stage II primary cutaneous malignant melanoma were treated by excision of 3.0 to 5.0 cm of surrounding skin down to and including the underlying fascia when the lesion exceeded 0.5 mm thickness (Breslow measurement). More conservative margins were taken in locations where such excisions would result in significant cosmetic or functional morbidity and for thinner lesions (less than 0.5 mm). Seven of 658 patients with clinical stage I disease (1.1%) and three of 14 patients with clinical stage II disease (21.4%) developed histologically verified local metastases within 5 cm of the primary excision scar or skin graft. Fifteen patients with stage I disease developed in-transit metastases (2.3%) at a site more than 5.0 cm proximal to the surgical scar or skin graft but not beyond the regional nodal group. Two patients with stage II disease who had developed local metastases also developed in-transit metastases (14.3%). No patient with a lesion less than 1.0 mm thick has had a local recurrence. Nine of the ten patients (90%) who developed local metastases and 12 of the 17 patients (70.6%) who developed in-transit metastases have also developed systemic metastases to date. Local and in-transit metastases following such definitive excision is a significant indicator of disseminated systemic metastatic melanoma.

Entities:  

Mesh:

Year:  1983        PMID: 6859994      PMCID: PMC1352934          DOI: 10.1097/00000658-198307000-00013

Source DB:  PubMed          Journal:  Ann Surg        ISSN: 0003-4932            Impact factor:   12.969


  21 in total

1.  Malignant melanoma.

Authors:  S CADE
Journal:  Ann R Coll Surg Engl       Date:  1961-06       Impact factor: 1.891

2.  MELANOMA. A TEN-YEAR RETROSPECTIVE SURVEY IN NEW ZEALAND.

Authors:  E C WATSON
Journal:  Aust N Z J Surg       Date:  1963-08

3.  Malignant melanomas of the skin. A study of the origin, development, aetiology, spread, treatment, and prognosis.

Authors:  N C PETERSEN; D C BODENHAM; O C LLOYD
Journal:  Br J Plast Surg       Date:  1962-04

4.  The role of groin dissection in the management of melanoma of the lower extremity.

Authors:  J G McCarthy; C D Haagensen; F P Herter
Journal:  Ann Surg       Date:  1974-02       Impact factor: 12.969

5.  Thickness, cross-sectional areas and depth of invasion in the prognosis of cutaneous melanoma.

Authors:  A Breslow
Journal:  Ann Surg       Date:  1970-11       Impact factor: 12.969

6.  En bloc resection of primary melanoma with regional lymph node dissection.

Authors:  J G Fortner; D Schottenfeld; B J Maclean
Journal:  Arch Surg       Date:  1975-05

7.  The site and time of recurrence of malignant melanoma.

Authors:  G W Milton
Journal:  Med J Aust       Date:  1966-02-19       Impact factor: 7.738

8.  Primary melanoma thickness correlated with regional lymph node metastases.

Authors:  D F Roses; M N Harris; D Hidalgo; Q J Valensi; N Dubin
Journal:  Arch Surg       Date:  1982-07

9.  The regressing thin malignant melanoma: a distinctive lesion with metastatic potential.

Authors:  M A Gromet; W L Epstein; M S Blois
Journal:  Cancer       Date:  1978-11       Impact factor: 6.860

10.  Surgical management for malignant melanoma of the trunk.

Authors:  D F Roses; M N Harris; S L Gumport
Journal:  Arch Surg       Date:  1981-03
View more
  6 in total

1.  Ipilimumab (yervoy) prolongs survival in advanced melanoma: serious side effects and a hefty price tag may limit its use.

Authors:  Chris Fellner
Journal:  P T       Date:  2012-09

2.  At least one centimetre for each millimetre.

Authors: 
Journal:  Br Med J (Clin Res Ed)       Date:  1984-10-20

Review 3.  Surgical management of primary melanoma.

Authors:  D Costello; A Powers; J Lynn; C W Cruse; D Reintgen
Journal:  Curr Oncol Rep       Date:  2000-07       Impact factor: 5.075

4.  Is sentinel lymph node mapping indicated for isolated local and in-transit recurrent melanoma?

Authors:  Katharine A Yao; Eddy C Hsueh; Richard Essner; Leland J Foshag; Leslie A Wanek; Donald L Morton
Journal:  Ann Surg       Date:  2003-11       Impact factor: 12.969

5.  Localization of 11C-radiopharmaceuticals in the Greene melanoma of hamsters.

Authors:  J H Turner; M Maziere; D Comar
Journal:  Eur J Nucl Med       Date:  1985

Review 6.  PET/CT variants and pitfalls in malignant melanoma.

Authors:  Nicolas Aide; Amir Iravani; Kevin Prigent; Diane Kottler; Ramin Alipour; Rodney J Hicks
Journal:  Cancer Imaging       Date:  2022-01-04       Impact factor: 3.909

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.